Efficacy and Safety of Abatacept or Infliximab Versus Placebo in ATTEST: A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate Authors and affiliations:
نویسندگان
چکیده
Denver Arthritis Clinic, Denver, CO, USA; Pontificial Catholic University, School of Medicine, Porto Alegre, Brazil; Health Research of Oklahoma, Oklahoma City, OK, USA; Arthritis & Osteoporosis Center, Flowood, MS, USA; Centro Medico Privado De Reumatologia, Tucuman, Argentina; St Augustine's Hospital, Durban, South Africa; Centro de Investigacion del Noroeste, Tijuana, Mexico; Bristol-Myers Squibb, Princeton, NJ, USA; Bristol-Myers Squibb, Pennington, NJ, USA; Paris-Descartes University, Medicine Faculty and UPRES-EA 4058; AP-HP, Cochin Hospital; Paris, France
منابع مشابه
Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study
OBJECTIVE To assess the efficacy and safety of abatacept in biological-naive patients with rheumatoid arthritis and an inadequate response to methotrexate treated in the long-term extension (LTE) of the ATTEST trial. METHODS Patients randomly assigned to abatacept, placebo or infliximab completing the 1-year double-blind period were eligible to receive abatacept ∼10 mg/kg in the open-label LT...
متن کاملEfficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
OBJECTIVES This double-blind trial evaluated the efficacy and safety of abatacept or infliximab vs placebo. The primary objective of this study was to evaluate the mean change from baseline in Disease Activity Score (based on erythrocyte sedimentation rates; DAS28 (ESR)) for the abatacept vs placebo groups at day 197. METHODS Patients with rheumatoid arthritis (RA) and an inadequate response ...
متن کاملCertolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
OBJECTIVE To evaluate the efficacy and safety of 2 dosage regimens of lyophilized certolizumab pegol (a novel PEGylated anti-tumor necrosis factor agent) as adjunctive therapy to methotrexate (MTX) in patients with active rheumatoid arthritis (RA) with an inadequate response to MTX therapy alone. METHODS In this 52-week, phase III, multicenter, randomized, double-blind, placebo-controlled, pa...
متن کاملEffects of Nigella sativa oil extract on inflammatory cytokine response and oxidative stress status in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled clinical trial
Objectives: Nigella sativa is a medicinal plant that has long been used in traditional medicine for treating various conditions. Numerous animal studies provided evidences that the seed may elicit a broad anti-inflammatory/anti-oxidant activity. The aim of the present clinical trial was to evaluate anti-inflammatory and antioxidant properties of Nigella sativa oil in patients with rheumatoid ar...
متن کاملSubcutaneous Abatacept vErsus Intravenous Abatacept: A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate
OBJECTIVE To compare the efficacy and safety of subcutaneous (SC) and intravenous (IV) abatacept. METHODS In this phase IIIb double-blind, double-dummy, 6-month study, patients with rheumatoid arthritis (RA) and inadequate responses to methotrexate were randomized to receive 125 mg SC abatacept on days 1 and 8 and weekly thereafter (plus an IV loading dose [∼10 mg/kg] on day 1) or IV abatacep...
متن کامل